Bone-marrow derived stem cell transplantation in patients undergoing left ventricular restoration surgery for dilated ischaemic end-stage heart failure: a randomised blinded controlled trial

niversity Hospitals Bristol NHS Foundation Trust (UK)0 个研究点目标入组 40 人开始时间: 2009年10月14日最近更新: 2017年5月8日

适应症

试验速览

暂无简介。

•1. Previous anterior myocardial infarction (with evidence of large surgically excludible scar at cardiac magnetic resonance imaging [MRI])
•2. Significant LV dilation (left ventricular end-systolic volume index [LVESVI] greater than or equal to 60 ml/m^2
•3. Left ventricular ejection fraction less than or equal to 35%
•4. New York Heart Association (NYHA) class III/IV and one episode of congestive heart failure (CHF) requiring medical attention
•5. Elective left ventricular restoration surgery indicated
•6. Elective CABG indicated to bypass stenoses or occlusions of coronary arteries
•7. Patient aged 16 years or over and under 80 years old, either sex

•1. Severe acute renal failure requiring dialysis or serum creatinine greater than or equal to 200 mmol/L
•2. Atrial fibrillation
•3. Malignancy
•4. Debilitating neurological disease
•5. Emergency operation for unstable angina
•6. Previous cardiac surgery/sternotomy
•7. Concomitant valve procedures
•8. History of significant ventricular arrhythmias
•9. History of pacemaker and/or defibrillator insertion
•10. Right ventricular (RV) failure
•11. Pulmonary hypertension greater than 60 mmHg (angiogram or Elixis)
•12. Known active infection
•13. Chronic inflammatory disease
•14. Contraindication for bone marrow aspiration
•15. Female subjects of childbearing potential

发起方

niversity Hospitals Bristol NHS Foundation Trust (UK)